Corbus Reports No Serious Psychiatric Events In Early Obesity-Pill Trial
Adverse events caused 12.9% of the highest-dose group to stop treatment; previously reported weight loss averaged 5% at 12 weeks.
Corbus Pharmaceuticals, which develops cancer and obesity treatments, reported no serious or severe psychiatric events in its early obesity-pill trial in an SEC filing Monday. The additional safety findings address the study's main goal, while adverse events caused 12.9% of participants at the highest dose to stop treatment.
Psychiatric Findings And Treatment Dropouts
Among 188 people receiving CRB-913, one reported temporary, moderate depressive symptoms. Another 15 reported mild irritability that cleared on its own without disrupting daily activities; none stopped treatment because of irritability.
No suicidal ideation was reported. All psychiatric events resolved, and half occurred within the first 28 days. Anxiety affected 3.1%, 8.2% and 4.8% of participants assigned to the 20 mg, 40 mg and 60 mg groups, respectively, versus 4.5% with placebo.
Adverse events prompted 21 treatment discontinuations, or 8.3% across the study, including placebo. Eight people stopped in each of the 40 mg and 60 mg groups, representing 13.1% and 12.9%, respectively; the placebo rate was 4.5%.
Gastrointestinal events were mild or moderate. Two drug recipients and one placebo recipient stopped because of them. At 60 mg, nausea and diarrhea each affected 22.6% of participants, while vomiting affected 1.6% and constipation 4.8%.
Weight Loss Was Already Public
Corbus's November 10 update had recounted the positive topline announcement. Monday's results added detail to a study whose main goal was safety and tolerability, with weight loss a secondary measure.
Average weight loss at 12 weeks was 5% at 60 mg, compared with 3.3% at 40 mg, 2.8% at 20 mg and 0% with placebo. Every tested dose produced a statistically significant result. Corbus said weight loss showed no sign of leveling off during treatment.
Among participants who completed the study at 60 mg, all lost weight and 44.4% lost at least 5%. The largest individual loss in that group was 13.4%. Waist circumference and body mass index also declined.
The trial enrolled 254 adults with obesity and without diabetes at 15 U.S. sites. Participants took a daily pill or placebo for 12 weeks, followed by four weeks of observation. Drug recipients began at 20 mg, with higher-dose groups stepping up every two weeks.
An Alternative Obesity Mechanism
CRB-913 blocks the cannabinoid type-1 receptor. Corbus designed it to limit brain exposure while acting elsewhere in the body, aiming to reduce the psychiatric risks associated with that mechanism.
Corbus CEO Yuval Cohen said in Monday's press release that “a significant number of people either do not adequately respond to or cannot tolerate these therapies,” referring to incretin-based treatments.
Corbus compared its safety findings with published GLP-1 studies, but its presentation cautioned that these were separate clinical settings, not head-to-head trials. The cited psychiatric safety studies tracked adverse events over longer periods than CRB-913's 12-week treatment course.
The company has no approved products on the market. Its development portfolio also includes the cancer treatment SUTA-E, also known as CRB-701. Corbus spent $70.1 million on research and development in 2025.
Corbus plans to discuss the results and further development of CRB-913 with the FDA. It is also evaluating whether the pill could be used alongside GLP-1 therapies.
Sources
- 8-K Filing — Corbus Pharmaceuticals Holdings, Inc. (CRBP) — SEC EDGAR
- Exhibit crbp-ex99_1.htm — Corbus Pharmaceuticals Holdings, Inc. 8-K exhibit — SEC EDGAR
- Exhibit crbp-ex99_2.htm — Corbus Pharmaceuticals Holdings, Inc. 8-K exhibit — SEC EDGAR
- Corbus Pharmaceuticals presents Phase 1b CANYON-1 clinical — globenewswire.com
- Corbus Pharmaceuticals Reports Q3 2026 Financial Results — globenewswire.com